GLOFITAMAB MONOTHERAPY IN PATIENTS WITH HEAVILY PRETREATED RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED ANALYSIS FROM A PHASE I/II STUDY